Nivolumab Plus Trastuzumab Deruxtecan Provides No Perceptible Clinical Benefit Over ADC Alone in Advanced HER2+ Breast Cancer

Via Peters

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer. The addition of nivolumab (Opdivo) to fam-trastuzumab deruxtecan-nxki (Enhertu) did not result in a marked clinical benefit in patients with locally advanced unresectable or […]

Trastuzumab Deruxtecan Yields Clinically Meaningful Outcomes in HER2-Low Metastatic Breast Cancer

Via Peters

Patients with HER2-low metastatic breast cancer achieved clinically meaningful improvement in progression-free survival following treatment with fam-trastuzumab deruxtecan-nxki. Treatment with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) yielded clinically meaningful improvements in key outcome measures for patients with HER2-low unresectable or metastatic breast cancer compared with investigator’s choice of chemotherapy, according to findings […]